Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Studies blood markers in families affected by brain and developmental conditions

Looks at blood markers in people with autism, epilepsy and related conditions.

Plain-language title generated from the registry record
Registry title: Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

Key facts

Where
Brooklyn and Phoenix, United StatesSee the 2 sites

Where in United States

  • State University of New York, DownstateBrooklyn, United StatesTaking people
  • Southwestern Research and Resource CenterPhoenix, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Southwest Autism Research & Resource Center
Trial code
NCT04322734
Record updated
23 April 2026
Original description
The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate.Read full original descriptionShow less

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate.

This study is currently recruiting.

There is no cost for visits or study-related exams.

Inclusion: ASD, as defined by either a gold standard measure for ASD diagnosis, the Autism Diagnostic Observation Schedule (ADOS); the Autism Diagnostic Interview-Revised (ADI-R); and/or a comprehensive assessment that is consistent with ASD, in the opinion of the principal investigator. For those the PI believes a prospective diagnosis of ASD is warranted, a formal diagnostic assessment will be scheduled at screening; 0 years through 17 years 11 months of age; 0 years to 17 years 11 months of age.

Exclusion: History of a significant adverse reaction to a prior blood draw; In females of reproductive age, pregnancy or plans to become pregnant; Any other historical event/information that may, in the opinion of the PI, be a reason to exclude the child from participation.

ClinicalTrials.gov NCT04322734